Optimistic Buy Rating for Enovis: Strong Growth, Margin Expansion, and Attractive Valuation

Jefferies analyst Young Li maintained a Buy rating on Enovis (ENOV – Research Report) on May 28 and set a price target of $60.00.

Young Li’s rating is based on several positive indicators for Enovis. The company has shown a strong start to 2025, with impressive growth figures in the first quarter, including significant improvements in gross margin and EBITDA. This growth is attributed to successful integration efforts and commercial execution, with further potential from new product launches and cross-selling opportunities.
Additionally, Enovis is focusing on expanding its margins and increasing free cash flow conversion, positioning itself well for future profitability. The company’s valuation is also attractive, trading below its peers, which suggests potential for multiple expansion. Overall, these factors contribute to Young Li’s optimistic outlook and Buy rating for Enovis.

According to TipRanks, Li is an analyst with an average return of -23.2% and a 21.88% success rate. Li covers the Healthcare sector, focusing on stocks such as Cooper Co, Alcon, and Hyperfine.

In another report released on May 13, Canaccord Genuity also maintained a Buy rating on the stock with a $70.00 price target.